Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: NAMPT

Summary for NAMPT

Gene information	Gene symbol	NAMPT
	Ensembl ID	ENSG00000105835
	Entrez ID	10135
	Gene name	nicotinamide phosphoribosyltransferase
	Synonyms	PBEF\|PBEF1
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: NAMPT

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.506754	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.360765	2.81e-13
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.270877	8.65e-24
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.298465	2.75e-13
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.288144	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.526805	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.396021	1.74e-17
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.462681	2.53e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.614233	1.25e-05
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.319714	2.78e-41
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.367076	1.33e-13
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.662645	3.24e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.288023	6.30e-06
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.532201	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.398927	5.08e-18
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.364582	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.278926	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.284727	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.606759	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.256395	4.25e-27
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-2.42943	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.307526	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.290617	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.272301	7.11e-14
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.46475	5.54e-23
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.364636	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.474869	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.39684	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.328744	9.60e-24

Top

Expression of NAMPT in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to NAMPT

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating NAMPT

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
NAMPT	hsa-miR-6869-5p	85.0191	NM_005746
NAMPT	hsa-miR-6873-3p	84.6731	NM_005746
NAMPT	hsa-miR-10399-5p	84.6381	NM_005746
NAMPT	hsa-miR-6504-3p	84.6381	NM_005746
NAMPT	hsa-miR-493-5p	84.1666	NM_005746
NAMPT	hsa-miR-548x-3p	83.7047	NM_005746
NAMPT	hsa-miR-548aj-3p	83.7047	NM_005746
NAMPT	hsa-miR-135a-5p	83.6763	NM_005746
NAMPT	hsa-miR-135b-5p	83.6763	NM_005746
NAMPT	hsa-miR-6124	83.4574	NM_005746
NAMPT	hsa-miR-7154-5p	83.221	NM_005746
NAMPT	hsa-miR-1297	83.0909	NM_005746
NAMPT	hsa-miR-2113	82.6393	NM_005746
NAMPT	hsa-miR-548am-3p	82.0235	NM_005746
NAMPT	hsa-miR-548ae-3p	82.0235	NM_005746
NAMPT	hsa-miR-548ah-3p	82.0235	NM_005746
NAMPT	hsa-miR-548j-3p	82.0235	NM_005746
NAMPT	hsa-miR-548aq-3p	82.0235	NM_005746
NAMPT	hsa-miR-2681-3p	81.9267	NM_005746
NAMPT	hsa-miR-26a-5p	81.502	NM_005746
NAMPT	hsa-miR-26b-5p	81.502	NM_005746
NAMPT	hsa-miR-584-3p	81.3964	NM_005746
NAMPT	hsa-miR-3529-3p	80.6578	NM_005746
NAMPT	hsa-miR-7157-3p	80.5538	NM_005746
NAMPT	hsa-miR-6737-3p	80.5538	NM_005746
NAMPT	hsa-miR-5008-3p	80.4551	NM_005746
NAMPT	hsa-miR-548ac	80.3834	NM_005746
NAMPT	hsa-miR-548bb-3p	80.3834	NM_005746
NAMPT	hsa-miR-548h-3p	80.3834	NM_005746
NAMPT	hsa-miR-548d-3p	80.3834	NM_005746
NAMPT	hsa-miR-548z	80.3834	NM_005746
NAMPT	hsa-miR-6828-5p	80.2136	NM_005746

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating NAMPT

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
NAMPT	metacluster_7.13	ZFX (directAnnotation).
NAMPT	cisbp__M01863	ZNF711 (inferredBy_Orthology).
NAMPT	metacluster_151.2	ZNF23 (directAnnotation).
NAMPT	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
NAMPT	transfac_pro__M05479	ZNF580 (directAnnotation).
NAMPT	metacluster_155.23	BCL11B; ZNF711; ZNF711 (directAnnotation). ZFY (inferredBy_Orthology).
NAMPT	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
NAMPT	homer__TWVGGTCCGC_HINFP	HINFP (directAnnotation).
NAMPT	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
NAMPT	jaspar__MA0079.5	SP1 (directAnnotation).
NAMPT	transfac_pro__M06035	ZNF749 (directAnnotation).
NAMPT	transfac_pro__M01861	ATF1 (directAnnotation).
NAMPT	kznf__ZNF282_Imbeault2017_OM_RCADE	ZNF282 (directAnnotation).
NAMPT	jaspar__MA1596.1	ZNF460 (directAnnotation).
NAMPT	metacluster_52.11	ZNF184 (directAnnotation).
NAMPT	metacluster_98.1	ZNF524 (directAnnotation).
NAMPT	taipale_tf_pairs__ETV2_SOX15_RSCGGAANNNNNNNYWTTGT_CAP_repr	ETV2; SOX15 (directAnnotation).
NAMPT	transfac_pro__M05667	ZNF35 (directAnnotation).
NAMPT	metacluster_53.2	ZNF8 (directAnnotation).
NAMPT	transfac_pro__M04814	RELA (directAnnotation).
NAMPT	transfac_pro__M06629	ZNF578 (directAnnotation).
NAMPT	transfac_pro__M04706	RELA (directAnnotation).
NAMPT	jaspar__MA1125.1	ZNF384 (directAnnotation).
NAMPT	tfdimers__MD00381	SOX10 (directAnnotation).
NAMPT	transfac_pro__M06577	ZNF594 (directAnnotation).
NAMPT	transfac_pro__M12441	ZNF281 (inferredBy_Orthology).
NAMPT	taipale_tf_pairs__HOXA4_RTMATTAN_HT	HOXA4 (directAnnotation).
NAMPT	metacluster_5.1	HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology).
NAMPT	metacluster_14.11	MITF; TFE3 (inferredBy_Orthology).
NAMPT	transfac_pro__M05475	ZBTB41 (directAnnotation).
NAMPT	transfac_pro__M06305	ZNF583 (inferredBy_Orthology).
NAMPT	transfac_pro__M04746	E2F1 (directAnnotation).
NAMPT	metacluster_65.8	ZNF343 (directAnnotation).
NAMPT	transfac_public__M00039	CREB1 (directAnnotation).
NAMPT	jaspar__MA0039.4	KLF4 (directAnnotation).
NAMPT	transfac_pro__M04595	SALL2 (directAnnotation).
NAMPT	jaspar__MA1117.1	RELB (directAnnotation).
NAMPT	transfac_pro__M08803	CREM (directAnnotation).
NAMPT	transfac_pro__M06818	ZNF592 (inferredBy_Orthology).
NAMPT	tfdimers__MD00527	IRF1; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF8; ZEB1 (directAnnotation).
NAMPT	hocomoco__FOXP1_HUMAN.H11MO.0.A	FOXP1 (directAnnotation).
NAMPT	metacluster_161.53	HOXA5 (directAnnotation).
NAMPT	tfdimers__MD00007	E2F1; IRF8 (directAnnotation).
NAMPT	metacluster_82.5	ZKSCAN8; ZNF205; ZNF227; ZNF594 (directAnnotation).
NAMPT	metacluster_161.33	DLX5 (directAnnotation).
NAMPT	metacluster_161.37	EN1 (directAnnotation).
NAMPT	metacluster_161.41	EVX1 (directAnnotation).
NAMPT	metacluster_161.56	HOXB5 (directAnnotation).
NAMPT	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
NAMPT	metacluster_161.63	HOXB8 (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
NAMPT	"CHS-828"	DB12980	small molecule
NAMPT	"Daporinad"	DB12731	small molecule
NAMPT	"GMX1777"	DB05217	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."